Donald Mathison: FDA’s overruling of advisory panel questioned
To the editor:
The drug company that produces Zohydro filed a lawsuit following the governor’s ban on its use in Massachusetts, claiming that because it had been approved by the FDA, Massachusetts was overstepping its authority. What seems to be lost in all this hoopla is the fact that the FDA’s advisory committee opposed its release by a vote of 11-2. How much confidence can you have in the FDA when the drug companies have considerably more weight than the advisory committee?